Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms.

Thomas E. Hutson,Toni K. Choueiri,Robert J. Motzer,Sun Young Rha,Anna Alyasova,Jaime R. Merchan,Howard Gurney,Avivit Peer,Toshio Takagi,Camillo Porta,Thomas Powles,Viktor Grünwald,Ugo De Giorgi,Ulka N. Vaishampayan,Manuela Schmidinger,Hilary Glen,Karla Rodriguez-Lopez,Dongyuan Xing,Lea Dutta,Masatoshi Eto

Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms.

2021

4562Background: The multicenter, open-label, randomized, phase 3 CLEAR study showed that LEN + EVE had a significant PFS benefit (HR 0.65, 95% CI 0.53-0.80, P<0.001) and improved objective response...

Keywords:

Internal medicine
objective response
Medicine
Renal cell carcinoma
Oncology
Everolimus
Post-hoc analysis
Lenvatinib
Sunitinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations